Summary
NanoBRIGHT will develop a new approach to optically interface with the brain, referred to as “photonic-physiology”: a new technique with high-translational appeal that exploits light-metals interactions to interface with the brain, targeting specific diseases including brain tumors, epilepsy and traumatic brain injuries. This will allow to reach the long-term vision of developing novel cutting-edge optical approaches to study and treat pathological conditions of the brain without using genetically-encoded proteins, which represent the main limitation for optogenetic techniques currently employed to interface with the neural tissue.
The approach will be based on a unique science-enabled technology exploiting the spatial selectivity properties of multimodal tapered optical fibers to activate a subset of high-density plasmonic hotspots along the taper. The resulting implantable devices will establish a new approach to interface with brain, striving at:
1- Demonstrate the capability of photonics for detecting and treating pathological conditions of the brain without the use of genetically-encoded proteins. We plan to exploit SERS to differentiate between primary and secondary brain tumors and to outline new methods to study oxidative stress in epileptogenic tissue.
2- Upscaling the range of physiological phenomena that can be controlled by light in vivo beyond those achieved so far by genetically encoded proteins, including vasodilation to locally increase permeability of the blood-brain-barrier thus enhancing pharmacological delivery in well-targeted regions of brain tumors.
3-Proving that unconventional combination between light-matter interactions and photonic-physiology can be used to analyze comorbidities between different diseases, testing the influence of brain tumors on epilepsy or tumor influence on the electrical activity of nearby and distal neural cells.
The approach will be based on a unique science-enabled technology exploiting the spatial selectivity properties of multimodal tapered optical fibers to activate a subset of high-density plasmonic hotspots along the taper. The resulting implantable devices will establish a new approach to interface with brain, striving at:
1- Demonstrate the capability of photonics for detecting and treating pathological conditions of the brain without the use of genetically-encoded proteins. We plan to exploit SERS to differentiate between primary and secondary brain tumors and to outline new methods to study oxidative stress in epileptogenic tissue.
2- Upscaling the range of physiological phenomena that can be controlled by light in vivo beyond those achieved so far by genetically encoded proteins, including vasodilation to locally increase permeability of the blood-brain-barrier thus enhancing pharmacological delivery in well-targeted regions of brain tumors.
3-Proving that unconventional combination between light-matter interactions and photonic-physiology can be used to analyze comorbidities between different diseases, testing the influence of brain tumors on epilepsy or tumor influence on the electrical activity of nearby and distal neural cells.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/828972 |
| Start date: | 01-05-2019 |
| End date: | 30-04-2024 |
| Total budget - Public funding: | 3 496 197,50 Euro - 3 496 197,00 Euro |
Cordis data
Original description
NanoBRIGHT will develop a new approach to optically interface with the brain, referred to as “photonic-physiology”: a new technique with high-translational appeal that exploits light-metals interactions to interface with the brain, targeting specific diseases including brain tumors, epilepsy and traumatic brain injuries. This will allow to reach the long-term vision of developing novel cutting-edge optical approaches to study and treat pathological conditions of the brain without using genetically-encoded proteins, which represent the main limitation for optogenetic techniques currently employed to interface with the neural tissue.The approach will be based on a unique science-enabled technology exploiting the spatial selectivity properties of multimodal tapered optical fibers to activate a subset of high-density plasmonic hotspots along the taper. The resulting implantable devices will establish a new approach to interface with brain, striving at:
1- Demonstrate the capability of photonics for detecting and treating pathological conditions of the brain without the use of genetically-encoded proteins. We plan to exploit SERS to differentiate between primary and secondary brain tumors and to outline new methods to study oxidative stress in epileptogenic tissue.
2- Upscaling the range of physiological phenomena that can be controlled by light in vivo beyond those achieved so far by genetically encoded proteins, including vasodilation to locally increase permeability of the blood-brain-barrier thus enhancing pharmacological delivery in well-targeted regions of brain tumors.
3-Proving that unconventional combination between light-matter interactions and photonic-physiology can be used to analyze comorbidities between different diseases, testing the influence of brain tumors on epilepsy or tumor influence on the electrical activity of nearby and distal neural cells.
Status
SIGNEDCall topic
FETOPEN-01-2018-2019-2020Update Date
27-04-2024
Images
No images available.
Geographical location(s)
Search
Organisations
-
| FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (Coördinator)
-
| AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
-
| CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
-
| FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III
-
| SORBONNE UNIVERSITE (SU)